A new study was published this week on Cell Death & Disease journal
A new study was published this week on Cell Death & Disease journal thanks to a collaboration between Prof. Gianluca Sala’s team, Mediapharma, and King’s College London scientists leaded by Prof. Tony Ng.
Lung cancer patients with mutant EGFR do benefit from the latest-generation drug Osimertinib, but unfortunately cancers can regrow due to resistance mechanisms and the lack of anti-tumour immune responses engaged by Osimertinib. In this work authors show that cancers can resist Osimertinib by exposing HER3. This resistance mechanism opens a therapeutic window to target HER3 with antibodies that engage an innate immune response dependent on macrophages and STING. This study sets a molecular base for future drug combinations and for stratification of patients that would benefit from Osimertinib and HER3-targeting therapies.